News | Stent Grafts | April 06, 2017

Endologix Announces Enrollment of First Patients in ELEVATE IDE Clinical Study

Trial will evaluate safety and effectiveness of Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms

April 6, 2017 — Endologix Inc. announced that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study.

ELEVATE IDE is the company’s pivotal clinical trial to evaluate the safety and effectiveness of the Ovation Alto Abdominal Stent Graft System for the repair of infrarenal abdominal aortic aneurysms (AAAs). The trial is approved to enroll 75 patients at up to 12 centers in the United States. The first procedure was performed by Steve Henao, M.D., chief, Division of Vascular Surgery at New Mexico Heart Institute.

The study principal investigator, Sean Lyden, M.D., chairman of the Department of Vascular Surgery at Cleveland Clinic commented, “We are excited to start treating patients in the ELEVATE IDE trial. The polymer technology in the device allows for active sealing in the aortic neck. The polymer sealing ring has proven durability in maintaining aneurysm exclusion to five years as reported in the Global Ovation Pivotal Trial. The repositioning of the sealing ring to 7mm below the top of the fabric will allow treatment of more challenging and complex anatomies in this trial.”

Ovation Alto is the newest device in the Ovation platform of abdominal stent graft systems, which has proven clinical results reported from the Ovation global pivotal trial and European Post-Market Registry. Ovation Alto expands endovascular aortic repair (EVAR) to treat more patients on IFU. This is achieved by the conformable O-rings with CustomSeal polymer that have been repositioned near the top of the endograft, providing seal just below the renal arteries.

The Ovation platform is the lowest profile U.S. Food and Drug Administration (FDA)-approved EVAR device, and it has been used successfully in the treatment of over 12,000 patients worldwide. Ovation Alto is an investigational device and currently not approved in any market.

Endologix CEO John McDermott said the company expects Ovation Alto could be available in the U.S. in 2019, based on the anticipated enrollment timeline.

For more information: www.endologix.com

Related Content

News | Cardiovascular Clinical Studies

May 23, 2022 — A specific protein in blood vessel cells plays a major role in the development of vascular and ...

Home May 23, 2022
Home
News | Cardiovascular Clinical Studies

May 20, 2022 — Results from a real-world study investigating safety and effectiveness of clopidogrel versus aspirin ...

Home May 20, 2022
Home
News | Cardiovascular Clinical Studies

May 11, 2022 — Hypertrophic cardiomyopathy is a heart disease that leads to a stressed, swollen heart muscle. Due to a ...

Home May 11, 2022
Home
News | Cardiovascular Clinical Studies

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

Home May 05, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – Patients with tricuspid regurgitation, a common and debilitating form of valvular heart disease, who ...

Home April 07, 2022
Home
News | Cardiovascular Clinical Studies

April 7, 2022 – While there are effective therapies to reduce the risk of heart disease by lowering low-density ...

Home April 06, 2022
Home
News | Cardiovascular Clinical Studies

March 25, 2022 – Despite recent efforts to improve women’s leadership in cardiovascular clinical trial research over the ...

Home March 25, 2022
Home
News | Cardiovascular Clinical Studies

We are launching something new—a Clinical Case of the Month—and we want you to contribute! Do you have a clinical case ...

Home February 17, 2022
Home
News | Cardiovascular Clinical Studies

February 8, 2022 — A new study is the first to show that a remote cognitive assessment could help with tracking patients ...

Home February 07, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
Subscribe Now